Antibody type
Monoclonal antibodies
Immunogen
Recombinant human MEK1 protein.
Specificity
This antibody detects endogenous levels of MEK1/2 and does not cross-react with related proteins.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Purification process
The antibody was affinity-purified from mouse ascites by affinity-chromatography using epitope-specific immunogen.
Other name
AA589381; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; EC 2.7.12.2; ERK activator kinase 1; ERK activator kinase 2; FLJ26075; MAP kinase kinase 1; MAP kinase kinase 2; MAP2K1; MAP2K2; MAPK/ERK kinase 1; MAPK/ERK kinase 2; MAPKK 1; MAPKK1; MAPKK2; MEK 1; MEKK1; Mitogen activated protein kinase kinase 1; Mitogen activated protein kinase kinase 2; Mitogen-activated protein kinase kinase 2, p45; MK2; MKK 1; MKK 2; MKK1; MKK2; MP2K1_HUMAN; PRKMK 1; PRKMK 2; Prkmk1; Prkmk2; protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1); Protein kinase, mitogen-activated, kinase 1; Protein kinase, mitogen-activated, kinase 2.
Background
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008],
Function
catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.,function:C
